OVARIAN CANCER ACTION.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -37.2%

  £2,609,197 → £1,637,463

• Cash

  -38.5%

  £2,199,055 → £1,351,478

• Net assets

  -26.5%

  £2,700,168 → £1,985,047

• Employees

  +17.6%

  17 → 20

• Operating profit

  -461.3%

  £215,815 → -£779,817

• Wages

  +14.7%

  £841,017 → £964,660

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. OVARIAN CANCER ACTION. 2007-07-18 → present
2. OVARIAN CANCER ACTION LTD 2007-01-04 → 2007-07-18
3. HELENE HARRIS MEMORIAL TRUST 2005-03-24 → 2007-01-04

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Moore Kingston Smith LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Significant events

• “A highlight of 2024 was the 15th Helene Harris Memorial Trust forum (HHMT), where the world's leading ovarian cancer scientists came together to define the breakthroughs needed to make this disease survivable.”
• “We also united with leading research charities in the US, Canada, and Australia to set up the Global Ovarian Cancer Research Consortium.”
• “The 15th HHMT focused on one of the biggest challenges in ovarian cancer: improving survival in high-grade serous ovarian cancer.”
• “A new Global Ovarian Cancer Research Consortium partnership that will push boundaries and drive progress on a global scale - leveraging our combined expertise.”
• “This year, we connected the Jewish community in England with a once-in-a-generation chance to find out if they carry the BRCA gene fault. With a free NHS testing programme available until October 2025, we created a powerful online campaign urging people to get tested and lower their ovarian cancer risk.”
• “In March, we shone a light on the shocking truth: despite a decade of breakthroughs, survival rates in the UK haven't improved in 10 years. That's why we called for urgent action from every corner of our community.”
• “In August, we refreshed our brand to cut through the silence around ovarian cancer. More than a new logo, it's about being harder to ignore - driving attention, awareness, and our mission to change the odds of survival.”
• “The AI Accelerator Grant offers $1 million in three-year funding, plus an optional $1 million in Azure credits and Al expertise from Microsoft Al for Good Labs. The recipient will be announced early next year.”
• “An online symptoms checker will launch later this year to help women recognise the signs of ovarian cancer sooner.”
• “With recent changes to NHS guidelines making more people eligible for BRCA testing, we'll refresh the calculator next year with the most up-to-date information.”
• “A generous four-year grant from the MIVA Foundation is helping drive research with the potential to help every woman with ovarian cancer get the treatment that's right for her.”
• “Our long-term partnership with Simplyhealth continued this year.”
• “NIXI Body, with whom we have been working since 2024, rallied their community to get involved.”
• “Lioness, footballer and Ovarian Cancer Action Ambassador Beth Mead, whose support continues to bring attention to a disease that often goes unnoticed.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.